HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure.
In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A link with previous antiretroviral therapy, intra-subtype B divergence across the integrase gene and transmission of integrase polymorphisms were also noted. Based on these findings, we would recommend ongoing surveillance of integrase mutations, and integrase region sequencing for patients prior to commencement of integrase inhibitors.
van Hal
Sebastiaan J
SJ
Centre for Infectious Diseases and Microbiology, ICPMR Westmead Hospital, University of Sydney, Westmead 2145, NSW, Australia. vanhal@gotalk.net.au
Herring
Belinda
B
Deris
Zaquan
Z
Wang
Bin
B
Saksena
Nitin K
NK
Dwyer
Dominic E
DE
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019427:HIV Integrase / Q000235:genetics* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D019429:Integrase Inhibitors / Q000627:therapeutic use; D009154:Mutation; D011110:Polymorphism, Genetic
D019380:Anti-HIV Agents; D019429:Integrase Inhibitors; D019427:HIV Integrase